MYOT

Across TCGA pan-cancer cohorts, MYOT RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of MYOT’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MYOT RNA is repressed in tumor relative to normal tissue. In most cancer types MYOT is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and THCA are the cancer types where MYOT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYOT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−2.092	<.001	12	view →
COAD	Male	II,III,IV	−1.590	<.001	11	view →
THCA	All	III,IV	−0.922	<.001	10	view →
STAD	All	All	−1.200	<.001	9	view →
HNSC	Male	All	−2.374	.002	8	view →
UCEC	All	All	−0.499	<.001	6	view →
READ	All	All	−1.691	.001	5	view →
KICH	All	II,III,IV	+0.622	.021	4	view →
KIRC	All	All	+0.354	<.001	3	view →
LIHC	Male	All	−0.123	<.001	3	view →
PRAD	All	All	−0.929	<.001	2	view →
PAAD	Male	All	+0.355	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

MYOT–BLCA

Open the BLCA breakdown →